Back to Archived Journals » Biosimilars » Volume 3 » default

Biosimilars ceased publishing in October 2016. All new submissions can be made to Biologics: Targets and Therapy. All articles that have been published in Biosimilars will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.

Archive: Volume 3, 2013

Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor

Bagalagel A, Mohammed A, MacDonald K, Abraham I

Biosimilars 2013, 3:55-62

Published Date: 27 August 2013

Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia

Mohammed A, Bagalagel A, MacDonald K, Abraham I

Biosimilars 2013, 3:45-53

Published Date: 27 August 2013

Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia

Bagalagel A, Mohammed A, MacDonald K, Abraham I

Biosimilars 2013, 3:35-43

Published Date: 21 August 2013

Current and future biosimilars: potential practical applications in rheumatology

Noaiseh G, Moreland L

Biosimilars 2013, 3:27-33

Published Date: 1 August 2013

Rituximab and biosimilars – equivalence and reciprocity

Qureshi ZP, Magwood JS, Singh S, Bennett CL

Biosimilars 2013, 3:19-25

Published Date: 14 June 2013

Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases

Desanvicente-Celis Z, Caro-Moreno J, Enciso-Zuluaga M, Anaya JM

Biosimilars 2013, 3:1-17

Published Date: 4 January 2013